Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Safety and efficacy of Ravulizumab

Safety and efficacy of Ravulizumab for pediatric patients with thrombocytic microangiopathy following hematopoetic stem cell transplantation

Description:

View complete study details here.

Interested in participating?

We are currently recruiting

Study Sponsor:

Alexion Pharmaceuticals, Inc.

Full IRB Study Title:

ALXN1210-TMA-314: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

IRB Study ID:

2021-018-ACH

If you are interested in this study or have questions about your child's eligibility, please contact:

Showers Family Center for Childhood Cancer and Blood Disorders. 330-543-8730

Lead Investigator

Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...